MX348735B - Celulas madre mesenquimales que expresan los receptores tnf-alfa. - Google Patents

Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Info

Publication number
MX348735B
MX348735B MX2013002845A MX2013002845A MX348735B MX 348735 B MX348735 B MX 348735B MX 2013002845 A MX2013002845 A MX 2013002845A MX 2013002845 A MX2013002845 A MX 2013002845A MX 348735 B MX348735 B MX 348735B
Authority
MX
Mexico
Prior art keywords
stem cells
mesenchymal stem
receptor
cells expressing
expressing tnf
Prior art date
Application number
MX2013002845A
Other languages
English (en)
Inventor
Danilkovitch Alla
Carter Diane
Tyrell Alicia
Bubnic Simon
Marcelino Michelle
Monroy Rodney
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of MX348735B publication Critical patent/MX348735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una composición que comprende una población de células madre mesenquimales que han sido criopreservadas a una temperatura de al menos -70°C o menos y descongeladas, la cual caracterizada porque comprende una población terapéuticamente efectiva de células madre mesenquimales; en donde la población terapéuticamente efectiva de células madre mesenquimales expresan receptor de TNF-a Tipo I en una cantidad de al menos 13 pg/106 células; y una solución de criopreservación; y en donde las células madre mesenquimales son no transfectadas y suprimen proliferación mononuclear de sangre periférica humana (Hpbmc).
MX2013002845A 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa. MX348735B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75915706P 2006-01-13 2006-01-13
PCT/US2007/000274 WO2007087139A2 (en) 2006-01-13 2007-01-05 MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR

Publications (1)

Publication Number Publication Date
MX348735B true MX348735B (es) 2017-06-27

Family

ID=38309740

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013002845A MX348735B (es) 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa.
MX2008008774A MX2008008774A (es) 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2008008774A MX2008008774A (es) 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Country Status (11)

Country Link
US (9) US20070258963A1 (es)
EP (3) EP1971679B1 (es)
CN (1) CN101370930A (es)
AU (1) AU2007208504B2 (es)
BR (1) BRPI0706529A2 (es)
CA (2) CA2635915C (es)
ES (1) ES2415855T3 (es)
HK (1) HK1151553A1 (es)
MX (2) MX348735B (es)
WO (1) WO2007087139A2 (es)
ZA (1) ZA200805609B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298862B1 (en) 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
KR20210122908A (ko) 2005-12-29 2021-10-12 안트로제네시스 코포레이션 태반 줄기 세포 집단
CN101370930A (zh) * 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
EP2633861B1 (en) 2008-08-22 2015-08-12 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US8367409B2 (en) 2008-11-19 2013-02-05 Anthrogenesis Corporation Amnion derived adherent cells
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US8956862B2 (en) * 2009-11-27 2015-02-17 Stempeutics Research Pvt. Ltd. Methods of preparing mesenchymal stem cells, compositions and kit thereof
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
US9408873B2 (en) 2010-08-23 2016-08-09 Kang Stem Biotech Co., Ltd. Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
EP2624845A4 (en) 2010-10-08 2015-09-09 Mesoblast Internat S Rl REINFORCED MSC PREPARATIONS
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
SG10201605518XA (en) 2011-07-06 2016-08-30 Cell Therapy Ltd Progenitor Cells Of Mesodermal Lineage
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
SG11201909856XA (en) * 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
US11701391B2 (en) 2017-10-24 2023-07-18 Dalia ELANI Methods of treating an ischemic disease
CN110938668A (zh) * 2019-11-21 2020-03-31 北京贝来生物科技有限公司 一种间充质干细胞生物学效力的检测方法
CA3188486A1 (en) * 2020-08-10 2022-02-17 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
WO2024009226A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl Cryopreserved intermediate and potency assay for same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5955257A (en) * 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
WO1999047163A2 (en) * 1998-03-18 1999-09-23 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
EP1078042A1 (en) 1998-05-22 2001-02-28 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP1218489B1 (en) * 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7144729B2 (en) * 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
ITTO20020311A1 (it) 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
US20060134596A1 (en) * 2003-05-08 2006-06-22 Anita Sjogren Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298862B1 (en) * 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20060063141A1 (en) * 2004-09-17 2006-03-23 Mcgann Locksley E Method of cryopreserving cells
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
CN101370930A (zh) * 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
KR100908481B1 (ko) 2006-04-24 2009-07-21 코아스템(주) 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법
BRPI0917993B8 (pt) 2008-08-14 2021-05-25 Mesoblast Int Sarl composições de célula-tronco mesenquimal purificada
EP2624845A4 (en) 2010-10-08 2015-09-09 Mesoblast Internat S Rl REINFORCED MSC PREPARATIONS
SG11201704781XA (en) 2014-12-23 2017-07-28 Mesoblast Int Sàrl Prevention of progressive heart failure
BR112020010079A2 (pt) 2017-11-22 2020-11-03 Mesoblast International Sàrl composições celulares e métodos de tratamento i
US20220143097A1 (en) 2019-01-02 2022-05-12 Mesoblast International Sárl Method for treating lower back pain
SG11202106795RA (en) 2019-01-03 2021-07-29 Mesoblast Int Sarl Method for improving visual acuity
US20220160776A1 (en) 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
SG11202112449SA (en) 2019-05-23 2021-12-30 Mesoblast Int Sarl Functional recovery from cerebral infarction
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
CN115361960A (zh) 2020-02-19 2022-11-18 迈索布拉斯特国际有限公司 用于治疗慢性移植物抗宿主病的方法
EP4117623A1 (en) 2020-03-11 2023-01-18 Mesoblast International Sàrl Method for treating inflammatory bowel disease ii

Also Published As

Publication number Publication date
EP1971679A2 (en) 2008-09-24
CN101370930A (zh) 2009-02-18
US20140248244A1 (en) 2014-09-04
EP2465922A3 (en) 2012-12-05
EP2465922B1 (en) 2018-08-01
US20090169522A1 (en) 2009-07-02
US20070258963A1 (en) 2007-11-08
MX2008008774A (es) 2008-09-26
HK1151553A1 (en) 2012-02-03
WO2007087139A3 (en) 2007-10-11
AU2007208504A1 (en) 2007-08-02
EP3287520A1 (en) 2018-02-28
US8486695B2 (en) 2013-07-16
WO2007087139A2 (en) 2007-08-02
US20130259841A1 (en) 2013-10-03
US11821004B2 (en) 2023-11-21
US20210171913A1 (en) 2021-06-10
CA2635915A1 (en) 2007-08-02
US20110189768A1 (en) 2011-08-04
EP1971679A4 (en) 2009-12-09
ES2415855T3 (es) 2013-07-29
US20120214178A1 (en) 2012-08-23
EP1971679B1 (en) 2013-04-10
CA2893204C (en) 2016-11-29
EP2465922A2 (en) 2012-06-20
ZA200805609B (en) 2009-04-29
BRPI0706529A2 (pt) 2011-03-29
CA2893204A1 (en) 2007-08-02
US20150004693A1 (en) 2015-01-01
CA2635915C (en) 2015-09-08
US20180087032A1 (en) 2018-03-29
AU2007208504B2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
RS20080336A (en) Activin-actriia antagonists and uses for promoting bone growth
MX2010008696A (es) Composiciones de proteina estabilizadas.
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MY159971A (en) Multipotent/pluripotent cells and methods
MX2009006651A (es) Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2009135905A3 (en) Mesenchymal stem cells and bone-forming cells
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
TW200611910A (en) Interferon-alpha polypeptides and conjugates
ATE553792T1 (de) Medizinische vorrichtungen mit verbundstoffen
WO2008060788A3 (en) Compositions, methods, and devices for treating liver disease
NZ612132A (en) Immunomodulation using placental stem cells
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
HK1106445A1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
SG158133A1 (en) Method for reversing multiple resistance in animal cells
EP1841781A4 (en) USE OF IL-22 FOR THE TREATMENT OF METABOLISM DISORDER
WO2009149359A3 (en) Survival predictor for diffuse large b cell lymphoma
AU2010207073A8 (en) Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
MX2009009822A (es) Composiciones y metodos para reducir niveles de h2s en bebidas fermentadas.
AU316238S (en) Lawning applicator for microbiological cultures
UA98447C2 (ru) АНТАГОНИСТЫ АКТИВИНА- ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ СОДЕЙСТВИЯ РОСТУ КОСТЕЙ